 The primary outcomes of the study will be to evaluate the systemic safety vital signs, laboratory evaluations and incidence of adverse events of the study drug assessed by Investigator taking into consideration the change from baseline to DAY 5, the local tolerability assessed by the patient every day during the treatment period and by Investigator. 